Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586883 | 0.97 | — | — | |
| SCHEMBL15588799 | 0.80 | F2 (0.50) | F2ALDH1A1CA1CA2CA12 | |
| SCHEMBL15588798 | 0.80 | F2 (0.50) | F2ALDH1A1CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL16766200 | 0.78 | F2 (0.48) | F2ALDH1A1CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL16766683 | 0.78 | F2 (0.48) | F2ALDH1A1CA1CA2CA12 | |
| SCHEMBL15588635 | 0.77 | F2 (0.46) | F2ALDH1A1CA1CA2CA12 | |
| SCHEMBL5178058 | 0.76 | F2 (0.46) | F2ALDH1A1CA1CA2CA12 | |
| SCHEMBL10593898 | 0.76 | F2 (0.52) | F2ALDH1A1CA1CA2CA12 | |
| SCHEMBL9988829 | 0.76 | F2 (0.46) | F2ALDH1A1CA1CA2CA12 | |
| SCHEMBL8348321 | 0.76 | F2 (0.46) | F2ALDH1A1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
| WO-2016142886-A2 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
| EP-2718288-B1 | SUBSTITUTED PIPERIDINES AS GPR119 MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-8921398-B2 | N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-8889691-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2014-11-18 | — | — | US | disclosed |
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2718288-A1 | SUBSTITUTED PIPERIDINES AS GPR119 MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| US-8569307-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-10-29 | — | — | US | disclosed |
| EP-2178869-B1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2013-06-12 | — | — | EP | disclosed |
| EP-1581213-A4 | 3,5-DISUBSTITUTED- 1,2,4 -OXADIAZOLES AND ANALOGS AS AC TIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008093960-A1 | NOVEL DIPEPTIDYL PEPTIDASE-IV INHIBITORS | LG LIFE SCIENCES, LTD. (KR) | 2008-08-07 | — | — | WO | disclosed |
| CN-100364531-C | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-7317029-B2 | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20070112003-A1 | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use of thereof | CYTOVIA, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-7144876-B2 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| CN-1756547-A | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA INC | 2006-04-05 | — | — | CN | disclosed |
| EP-1581213-A1 | 3,5-DISUBSTITUTED- 1,2,4 -OXADIAZOLES AND ANALOGS AS AC TIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004058253-A1 | 3,5-DISUBSTITUTED-[1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | F2 3596/4885ALDH1A1 2800/4885CA1 1571/4885 |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP3, CASP2 | F2 2655/4885ALDH1A1 155/4885CA1 1863/4885 |
| US-20070112003-A1 | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use of thereof | CASP1, CASP3, CASP2 | F2 2898/4885ALDH1A1 205/4885CA1 2469/4885 |
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | PDCD1, CD274, PDCD1LG2 | F2 3300/4885ALDH1A1 145/4885CA1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.